A tiny CAR-T trial kept two HIV patients off daily drugs for up to 20 months, hinting at durable immune control—not a cure.
Key takeaways
- **Two people with HIV have stayed off antiretroviral therapy after a single infusion of engineered immune cells, with viral levels undetectable for roughly 10 and 20 m...
- The finding does not establish a cure. It does something more specific: it suggests CAR-T cell therapy, already used in tough-to-treat cancers, may be able to trai...
- > “These are early days. If we can provide the proof-of-concept that this approach is both safe and effective, then there are lots of ways in which it can be optimized...
- CAR-T Pushes HIV Research Toward Durable Immune Control
👉 Read the full breakdown on MLXIO
Canonical source: https://mlxio.com/science/car-t-hiv-therapy
